

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
6 July 2006 (06.07.2006)

PCT

(10) International Publication Number
WO 2006/071730 A1

(51) International Patent Classification:

C07D 231/22 (2006.01) A61P 25/28 (2006.01)
C07D 231/20 (2006.01)

(21) International Application Number:

PCT/US2005/046606

(22) International Filing Date:

22 December 2005 (22.12.2005)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/638,369 27 December 2004 (27.12.2004) US

(71) Applicants (for all designated States except US):
ASTRAZENECA AB [SE/SE]; Astrazeneca R & d
Sodertalje, S-151 85 Sodertalje (SE). **NPS PHARMA-
CEUTICALS, INC.** [US/US]; 383 Colorow Drive, Salt
Lake City, Utah 84108 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BALESTRA, Michael** [US/US]; 1800 Concord Pike, Wilmington, Delaware 19850 (US). **BUNTING, Heather** [US/US]; 1800 Concord Pike, Wilmington, Delaware 19850 (US). **CHEN, Deborah** [US/US]; 1800 Concord Pike, Wilmington, Delaware 19850 (US). **EGLE, Ian** [CA/CA]; 101 College Street, 8th Floor, Toronto, Ontario M5G 1L8 (CA). **FORST, Janet** [US/US]; 1800 Concord Pike, Wilmington, Delaware 19850 (US). **FREY, Jennifer** [CA/CA]; 101 College Street, 8th Floor, Toronto, Ontario M5G 1L8 (CA). **ISAAC, Methvin** [CA/CA]; 101 College Street, 8th Floor, Toronto, Ontario M5G 1L8 (CA). **MA, Fupeng** [CA/CA]; 101 College Street, 8th Floor, Toronto, Ontario M5G 1L8 (CA). **NUGIEL, David** [US/US]; 1800 Concord Pike, Wilmington, Delaware 19850 (US). **SLASSI, Abdelmalik** [CA/CA]; 101 College Street, 8th Floor, Toronto, Ontario M5G 1L8 (CA). **STEELMAN, Gary** [US/US]; 1800 Concord Pike, Wilmington,

Delaware 19850 (US). **SUN, Guang-ri** [CA/CA]; 101 College Street, 8th Floor, Toronto, Ontario M5G 1L8 (CA). **SUNDAR, Babu** [US/US]; 1800 Concord Pike, Wilmington, Delaware 19850 (US). **UKKIRAMAPANDIAN, Radhakrishnan** [IN/US]; 383 Colorow Drive, Salt Lake City, Utah 84108 (US). **URBANEK, Rebecca A.** [US/US]; 1800 Concord Pike, Wilmington, Delaware 19850 (US). **WALSH, Sally** [US/US]; 1800 Concord Pike, Wilmington, Delaware 19850 (US).

(74) Agent: **MEIKLE, Andrew D.**; Birch, Stewart, Kolasch & Birch, LLP, 8110 Gatehouse Road, Suite 100 East, P.O. Box 747, Falls Church, Virginia 22040-0747 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PYRAZOLONE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS

(57) Abstract: Compounds of Formula (I), wherein R¹, R², R³, R⁴, R⁵, R⁶, X, and n are as defined for Formula (I) in the description, processes for the preparation of the compounds and new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and the use of the compounds in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction.



WO 2006/071730 A1